Skip to main content
PHGUF logo

Pharming Group N.V. (PHGUF) Stock Price & Analysis

Pharming Group N.V. (PHGUF) — price $1.26 (0.00%), as of the Nov 18, 2026 trading session; market cap $892M.

Educational signal · not a buy or sell recommendation · How to read this

$1.26 $0.00 (0.00%) Market Cap $892M

Pharming Group N.V. · PHGUF

Pharming Group N.V. is a biopharmaceutical company specializing in protein replacement therapies and precision medicines for rare diseases, with its flagship product Ruconest for hereditary angioedema.

Price as of Nov 18, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • MGTX · MeiraGTx Holdings plc · 63 /100
  • SGP · SpyGlass Pharma, Inc. Common Stock · 64 /100
  • RIGL · Rigel Pharmaceuticals, Inc. · 88 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.26
Change on the day0.00%
52-week range$0.9285 – $2.17
Market capitalisation$892M
Price / earnings (trailing)35.00
Shares traded on the day1.0K

Price & events

Other perspectives

Council score for Pharming Group (PHGUF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Neutral
ROE Weak
Gross Margin Strong

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Pharming Group (PHGUF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Pharming Group N.V. (PHGUF) is the company analyzed here. It employs 407 people and is led by Kenneth Lynard. In Q3 FY2026 it reported revenue of $116M and net income of $22M. The market values it at $892M.

2 · Latest results

What do the latest results show for Pharming Group (PHGUF)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $116M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$116M$22M$0.03 (diluted)
Q2 FY2026$90M$2M$0.0019 (diluted)
Q1 FY2026$72M-$5M-$0.01 (diluted)
Q4 FY2025$107M$5M$0.01 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Pharming Group (PHGUF)?

Short answer · as of

The distress and quality screens read Altman Z 3.19 · Piotroski F 5. Trailing ratios: ROE 8.7% · ROA 6.4% · current ratio 3.23.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PHGUF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PHGUF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Investor Questions: PHGUF Stock

These answers are editorial: 1 of these 8 answers is drawn from the PHGUF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is PHGUF a good stock to buy?

Stock Expert AI does not rate PHGUF buy, sell or hold. Pharming Group N.V. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PHGUF stock price today?

The last price recorded for Pharming Group N.V. (PHGUF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does Pharming Group N.V. navigate the complex regulatory approval processes for its rare disease therapies?

Pharming Group N.V. navigates regulatory approval processes by focusing on rare diseases, which often qualify for orphan drug designations. These designations can provide incentives such as market exclusivity and potentially expedited review pathways from regulatory bodies like the FDA and EMA.

What are the key factors to evaluate for PHGUF?

Evaluate PHGUF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. While currently approved for acute HAE attacks, further research or label extensions could broaden its use. Not financial advice.

How frequently does PHGUF data refresh on this page?

PHGUF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PHGUF's recent stock price performance?

Pharming Group N.V. (PHGUF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Flagship product Ruconest for hereditary angioedema with established market presence. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PHGUF overvalued or undervalued right now?

The trailing P/E of Pharming Group N.V. (PHGUF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research PHGUF before investing?

Before investing in Pharming Group N.V. (PHGUF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 10 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.